VHL 抗体 (C-Term)
-
- 抗原 See all VHL 抗体
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
-
抗原表位
- AA 181-210, C-Term
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This VHL antibody is un-conjugated
-
应用范围
- Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- 纯化方法
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- 免疫原
- This VHL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 181-210 amino acids from the C-terminal region of human VHL.
- 克隆位点
- RB18668
- 亚型
- Ig Fraction
- Top Product
- Discover our top product VHL Primary Antibody
-
-
- 应用备注
- WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100. FC: 1:10~50
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
- 有效期
- 6 months
-
-
Protective effect of salidroside against bone loss via hypoxia-inducible factor-1α pathway-induced angiogenesis." in: Scientific reports, Vol. 6, pp. 32131, (2018) (PubMed).
: "Salidroside accelerates fracture healing through cell-autonomous and non-autonomous effects on osteoblasts." in: Cell and tissue research, Vol. 367, Issue 2, pp. 197-211, (2017) (PubMed).
: "
-
Protective effect of salidroside against bone loss via hypoxia-inducible factor-1α pathway-induced angiogenesis." in: Scientific reports, Vol. 6, pp. 32131, (2018) (PubMed).
-
- 抗原
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- 别名
- VHL (VHL 产品)
- 别名
- HRCA1 antibody, RCA1 antibody, VHL1 antibody, pVHL antibody, BcDNA:RH61560 antibody, CG13221 antibody, DVhl antibody, Dmel\\CG13221 antibody, Dvhl antibody, VHL antibody, d-VHL antibody, d-vhl antibody, dVHL antibody, dmVHL antibody, vhl antibody, rca1 antibody, vhl1 antibody, hrca1 antibody, zgc:158722 antibody, Vhlh antibody, von Hippel-Lindau tumor suppressor antibody, von Hippel-Lindau antibody, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antibody, von Hippel-Lindau disease tumor suppressor antibody, VHL antibody, Vhl antibody, vhl antibody, CpipJ_CPIJ009992 antibody
- 背景
- Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.
- 分子量
- 24153
- 基因ID
- 7428
- NCBI登录号
- NP_000542, NP_937799
- UniProt
- P40337
- 途径
- Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
-